Reunion Neuroscience
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
257 S 25th St, Philadelphia, Pennsylvani...Website
www.reunionneuro.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Reunion Neuroscience
Reunion Neuroscience is a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions. Reunion is actively investigating the use of its lead product candidate, RE104, in postpartum depression, adjustment disorder and generalized anxiety disorder, as well as in additional neuropsychiatric indications where there remains a significant unmet need that is not addressed by the current standard of care. Reunion has advanced a lead candidate, RE245, from its non-psychedelic discovery program and plans to file an IND in 2026.Explore more
Reunion Neuroscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Reunion Neuroscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Reunion Neuroscience launches new products
Earning: See what the market has to say on Reunion Neuroscience recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Reunion Neuroscience
Reunion Neuroscience, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Reunion Neuroscience is spiking on competitors!
Check if Reunion Neuroscience has recently received funding, and reach out quickly before it becomes old news!
Click to see if Reunion Neuroscience had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Reunion Neuroscience has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Reunion Neuroscience
Compare insights from companies similar to Reunion Neuroscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Reunion Neuroscience is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Reunion Neuroscience is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Reunion Neuroscience.
Reunion Neuroscience financials insights
Gather financial insights about Reunion Neuroscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$133M
2025
Series A
$30M
Reunion Neuroscience Tech Stack
A closer look at the technologies used by Reunion Neuroscience
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Reunion Neuroscience News & Media
Reunion Neuroscience to Present Full Data from RECONNECT Phase 2 Clinical Trial at Upcoming ASCP and APA Annual Meetings
MORRISTOWN, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced that it will share the full results of the RECONNECT, a Phase 2 trial evaluating luvesilocin in adult female patients with moderate-to-severe postpartum depression (PPD), in an oral presentatioU.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status
-- Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data -- -- Aligned with U.S. Food and Drug Administration on Registrational Path for Luvesilocin in Postpartum Depression (PPD); On Track to Initiate Phase 3 Trial in 2026 -- MORRISTOWN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generatReunion Neuroscience to Participate in Upcoming Investor Conferences
MORRISTOWN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions, today announced its participation in the following upcoming conferences:Reunion Neuroscience Presents Full Data from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) at ACNP Annual Meeting
-- Met Primary Endpoint with 30mg Dose of RE104 with 23.0-Point Total Score Reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) on Day 7 (p=0.0094) -- -- Demonstrated Rapid and Durable Efficacy Starting as Early as Day 1 and Continuing Through Day 28, with Substantial and Clinically Significant Improvements Across Key Measures of Mood and Anxiety -- -- Aligned with U.S. Food and Drug Administration (FDA) on Registrational Path for RE104 in PPD; On Track to
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Reunion Neuroscience
Sign Up For FreeTo access detailed company insights
Reunion Neuroscience is a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic-inspired therapeutic solutions. Reunion is actively investigating the use of its lead product candidate, RE104, in postpartum depression, adjustme... Read More
